Mr. Andre Larente reports

DIAGNOS ANNOUNCES AMENDMENT TO CONVERTIBLE DEBENTURES

Diagnos Inc. intends to amend the terms of an aggregate amount of $120,000 of unsecured convertible debentures issued as part of a private placement of units initially announced on March 28, 2022, as follows:

• The maturity date, initially set for March 25, 2025, is extended to March 25, 2026.
• For the extended period from March 25, 2025, to March 25, 2026, the yearly interest rate is increased from 8 per cent to 10 per cent.

All other provisions of the debentures will remain unchanged and fully in effect during the extension period.

The amendment remains subject to the TSX Venture Exchange acceptance, as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.